drugset / Trial / NCT01140737
A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas
Phase 2
Completed
145 enrolled
Sheffield Teaching Hospitals NHS Foundation Trust
Cancer Research UK · collabPfizer · collabUniversity of Birmingham · collab
NaSingle-groupOpen-labelTreatment
Summary
The study objective is to evaluate the therapeutic activity, safety and tolerability of axitinib in patients with advanced/metastatic soft tissue sarcoma who are unsuitable for or have relapsed after standard chemotherapy. The therapeutic activity will be separately assessed in angiosarcoma, synovial sarcoma, leiomyosarcomas and other sarcomas.
Timeline
- Start
- 2010-08-31
- Primary completion
- 2016-06-11
- Completion
- 2019-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | 5 mg | Oral |